JACC:CTD患者6MW负荷超声心动图预测未来显性肺动脉高压

2015-07-21 崔倩 译 MedSci原创

结缔组织病(CTD)患者早期检测肺动脉高压(PH)是至关重要的,这样可以确保患者的疾病及时得到治疗。运动负荷测试已经用于筛选患者以试图识别出早期的PH。最近的研究已经描述了异常平均肺动脉压(mPAP)-心输出量(Q)的反应作为具有评估疾病状态的可能性。    这项研究推测,通过6分钟步行(6MW)负荷超声心动图获得的肺循环压力 - 流的关系会更好地描述PH的差异进展以

结缔组织病(CTD)患者早期检测肺动脉高压(PH)是至关重要的,这样可以确保患者的疾病及时得到治疗。运动负荷测试已经用于筛选患者以试图识别出早期的PH。最近的研究已经描述了异常平均肺动脉压(mPAP)-心输出量(Q)的反应作为具有评估疾病状态的可能性。
    
这项研究推测,通过6分钟步行(6MW)负荷超声心动图获得的肺循环压力 - 流的关系会更好地描述PH的差异进展以及随访期间预测PH的发展。
    
研究人员对78例CTD患者在基线和随访期间进行了前瞻性地6MW应激超声心动图研究(年龄58±12岁;9%为男性)。所有患者每年进行超声心动图的随访研究,长达5年时间。
    
在32个月(范围:15〜62个月)的中位随访期间内,16例患者达到了PH发展的临床终点,随访期间无死亡病例。所有16例患者的PH通过右心脏导管(mPAP≥25mmHg,肺毛细血管楔压≤15mmHg)证实存在。在Cox比例风险生存模型中,6MW的距离(危险比[HR]:0.99;P=0.010),早期舒张三尖瓣环运动速度(HR:0.79;P=0.025),以及通过6MW应激得到的ΔmPAP/ΔQ(HR :1.10;P=0.005)均与PH的发展有关。在连续Cox模型中,在6MW距离(卡方,6.6)的基础上,通过ΔmPAP/ΔQ模型得到改善(卡方:14.4;P=0.019)。使用受试者工作特征曲线,研究人员发现,预测肺动脉高压发展的ΔmPAP/ΔQ的最佳截止值是>3.3mmHg/L/min。
   
该6MW负荷超声心动图无创性的提供了CTD患者PH发展的增量预后价值。这是一个单中心前瞻性队列研究。还需较大的多中心研究来证实这一结果。

原始出处:


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1650997, encodeId=1b1f165099ec5, content=<a href='/topic/show?id=2aa35090181' target=_blank style='color:#2F92EE;'>#心动图#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50901, encryptionId=2aa35090181, topicName=心动图)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8a7624121693, createdName=zhu_jun9845, createdTime=Fri Jul 01 14:10:00 CST 2016, time=2016-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1925129, encodeId=a06619251297e, content=<a href='/topic/show?id=26d633354c9' target=_blank style='color:#2F92EE;'>#动脉高压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33354, encryptionId=26d633354c9, topicName=动脉高压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Tue Oct 20 11:10:00 CST 2015, time=2015-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1853375, encodeId=15c618533e518, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Sun May 01 02:10:00 CST 2016, time=2016-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1325066, encodeId=a5a81325066ae, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Thu Jul 23 10:10:00 CST 2015, time=2015-07-23, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1650997, encodeId=1b1f165099ec5, content=<a href='/topic/show?id=2aa35090181' target=_blank style='color:#2F92EE;'>#心动图#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50901, encryptionId=2aa35090181, topicName=心动图)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8a7624121693, createdName=zhu_jun9845, createdTime=Fri Jul 01 14:10:00 CST 2016, time=2016-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1925129, encodeId=a06619251297e, content=<a href='/topic/show?id=26d633354c9' target=_blank style='color:#2F92EE;'>#动脉高压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33354, encryptionId=26d633354c9, topicName=动脉高压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Tue Oct 20 11:10:00 CST 2015, time=2015-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1853375, encodeId=15c618533e518, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Sun May 01 02:10:00 CST 2016, time=2016-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1325066, encodeId=a5a81325066ae, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Thu Jul 23 10:10:00 CST 2015, time=2015-07-23, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1650997, encodeId=1b1f165099ec5, content=<a href='/topic/show?id=2aa35090181' target=_blank style='color:#2F92EE;'>#心动图#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50901, encryptionId=2aa35090181, topicName=心动图)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8a7624121693, createdName=zhu_jun9845, createdTime=Fri Jul 01 14:10:00 CST 2016, time=2016-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1925129, encodeId=a06619251297e, content=<a href='/topic/show?id=26d633354c9' target=_blank style='color:#2F92EE;'>#动脉高压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33354, encryptionId=26d633354c9, topicName=动脉高压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Tue Oct 20 11:10:00 CST 2015, time=2015-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1853375, encodeId=15c618533e518, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Sun May 01 02:10:00 CST 2016, time=2016-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1325066, encodeId=a5a81325066ae, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Thu Jul 23 10:10:00 CST 2015, time=2015-07-23, status=1, ipAttribution=)]
    2016-05-01 hbwxf
  4. [GetPortalCommentsPageByObjectIdResponse(id=1650997, encodeId=1b1f165099ec5, content=<a href='/topic/show?id=2aa35090181' target=_blank style='color:#2F92EE;'>#心动图#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50901, encryptionId=2aa35090181, topicName=心动图)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8a7624121693, createdName=zhu_jun9845, createdTime=Fri Jul 01 14:10:00 CST 2016, time=2016-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1925129, encodeId=a06619251297e, content=<a href='/topic/show?id=26d633354c9' target=_blank style='color:#2F92EE;'>#动脉高压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33354, encryptionId=26d633354c9, topicName=动脉高压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Tue Oct 20 11:10:00 CST 2015, time=2015-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1853375, encodeId=15c618533e518, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Sun May 01 02:10:00 CST 2016, time=2016-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1325066, encodeId=a5a81325066ae, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Thu Jul 23 10:10:00 CST 2015, time=2015-07-23, status=1, ipAttribution=)]

相关资讯

Am J Cardiol:应用他汀类药物与结缔组织病风险降低相关

  美国一项研究表明,他汀类应用与结缔组织病(CTD)风险降低具有相关性。论文于6月13日在线发表于《美国心脏病学杂志》(Am J Cardiol)。   此项研究共纳入13640例他汀类应用者和32848例未应用者。基于41项变量创建倾向评分,并按1:1比率将他汀类应用者和未应用者进行配对。转归指标为国际疾病分类(ICD)诊断符合CTD的编码出现。   结果显示,共有69